Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
101M
-
Number of holders
-
217
-
Total 13F shares, excl. options
-
78.9M
-
Shares change
-
+1.26M
-
Total reported value, excl. options
-
$1.93B
-
Value change
-
+$31.9M
-
Put/Call ratio
-
0.53
-
Number of buys
-
93
-
Number of sells
-
-86
-
Price
-
$24.50
Significant Holders of Beam Therapeutics Inc. - Common Stock (BEAM) as of Q3 2024
247 filings reported holding BEAM - Beam Therapeutics Inc. - Common Stock as of Q3 2024.
Beam Therapeutics Inc. - Common Stock (BEAM) has 217 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.9M shares
of 101M outstanding shares and own 78.45% of the company stock.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (8.21M shares), VANGUARD GROUP INC (7.84M shares), BlackRock, Inc. (7.75M shares), ARK Investment Management LLC (6.53M shares), ARCH Venture Management, LLC (4.83M shares), FMR LLC (4.21M shares), STATE STREET CORP (3.93M shares), Sumitomo Mitsui Trust Group, Inc. (3.55M shares), Nikko Asset Management Americas, Inc. (3.55M shares), and MWG Management Ltd. (2.27M shares).
This table shows the top 217 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.